The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KYMR | +26.22% | +69.96% | +11.19% | +86% |
| S&P | +18.33% | +108.18% | +15.79% | +103% |
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.48M | -55.3% |
| Gross Profit | $9.39M | -60.5% |
| Gross Margin | 81.84% | -10.8% |
| Market Cap | $2.84B | 55.2% |
| Market Cap / Employee | $13.04M | 33.1% |
| Employees | 218 | 20.4% |
| Net Income | -$76.61M | -82.1% |
| EBITDA | -$82.47M | -68.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $335.82M | 396.7% |
| Accounts Receivable | $40.00M | 2247.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $72.05M | -4.9% |
| Short Term Debt | $13.67M | 10.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.15% | -5.7% |
| Return On Invested Capital | -24.56% | 10.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$60.58M | -27.2% |
| Operating Free Cash Flow | -$59.88M | -39.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.43 | 2.92 | 2.13 | 3.61 | 40.35% |
| Price to Sales | 41.15 | 68.36 | 37.25 | 78.52 | 218.83% |
| Price to Tangible Book Value | 3.43 | 2.92 | 2.13 | 3.61 | 40.35% |
| Enterprise Value to EBITDA | -44.80 | -35.76 | -25.10 | -35.54 | -0.95% |
| Return on Equity | -26.0% | -36.4% | -32.2% | -33.3% | 18.02% |
| Total Debt | $88.23M | $87.76M | $86.33M | $85.71M | -2.80% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
